SEARCH

SEARCH BY CITATION

References

  • 1
    Calne RY, Rolles K, White DJ, Thiru S et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 10331036.
  • 2
    Shihab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol 1996; 16: 536547.
  • 3
    Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2: 477479.
  • 4
    Schrama YC, Joles JA, Van Tol A, Boer P, Koomans HA, Hene RJ. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000; 69: 376383.
  • 5
    Woolfson RG, Neild GH. Cyclosporin nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 1997; 12: 20542056.
  • 6
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557565.
  • 7
    Morris PJ, Chapman JR, Allen RD et al. Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. Lancet 1987; 1: 586591.
  • 8
    Morris PJ, French ME, Dunnill MS et al. A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 1983; 36: 273277.
  • 9
    MacPhee IA, Bradley JA, Briggs JD et al. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 1998; 66: 11861192.
  • 10
    Ducloux D, Fournier V, Bresson-Vautrin C et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report. Transplantation 1998; 65: 15041506.
  • 11
    Schnuelle P, Van Der Heide JH, Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536543.
  • 12
    Weir MR, Blahut S, Drachenburg C et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379386.
  • 13
    Smak Gregoor PJ, De Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 13651373.
  • 14
    Afzali B, Shah S, Chowdhury P, O'Sullivan H, Taylor J, Goldsmith D. Low-Dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005; 79: 304309.
  • 15
    Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 10361042.
  • 16
    Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 12521260.
  • 17
    Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777786.
  • 18
    Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364370.
  • 19
    Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 2228.
  • 20
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 15601567.
  • 21
    Lai WJ, Chiang YJ, Chen Y, Chu SH. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? Transplant Proc 2004; 36: 20562057.
  • 22
    Wu MJ, Shu KH, Cheng CH, Chen CH. Sirolimus in chronic allograft nephropathy. Transplant Proc 2004; 36: 20532055.
  • 23
    Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 12441247.
  • 24
    Ram Peddi V, Jensik S, Pescovitz M et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19: 130136.
  • 25
    Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 18691875.
  • 26
    Citterlo F, Scata MC, Violi P et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003; 35: 12921294.
  • 27
    Thervet E, Morelon E, Ducloux D et al. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Clin Transplant 2000; 14: 561566.
  • 28
    Smak Gregoor PJ, Van Gelder T, Van Besouw NM, Van Der Mast BJ, IJzermans JN, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143148.
  • 29
    Ducloux D, Motte G, Billerey C et al. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int 2002; 15: 387392.
  • 30
    Guba M, Von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128135.
  • 31
    Lee S, Coco M, Greenstein SM, Schechner RS, Tellis VA, Glicklich DG. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin Transplant 2005; 19: 162167.
  • 32
    Kaczmarek I, Groetzner J, Adamidis I et al. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004; 4: 10841088.
  • 33
    Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78: 13621366.